# BIOGEN INC. (BIIB) FY2025 Annual P&L / Income Statement - Company: BIOGEN INC. (BIIB) - Period: 2025-01-01 to 2025-12-31 - Filing: FY2025 10-K, filed 2026-02-06, accession number 0000875045-26-000013 - Page: https://plicit.ai/financials/biib/fy2025-annual-income-statement - Chart image: https://plicit.ai/charts/biib-fy2025-annual-income-statement-sankey.png ## Chart details: Revenue by Product and Service by Geography Income statement for 2025-01-01 through 2025-12-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,890,600,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,404,200,000 US dollars - **Gross profit (calculated)**: 7,486,400,000 US dollars - **Operating expenses (calculated)**: 5,929,900,000 US dollars - **Operating profit (calculated)**: 1,556,500,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense**: 1,556,500,000 US dollars - **Income tax (benefit) expense**: 263,600,000 US dollars - **Net income**: 1,292,900,000 US dollars - **AVONEX - UNITED STATES**: 482,900,000 US dollars - **AVONEX - Rest of World**: 212,600,000 US dollars - **BENEPALI - UNITED STATES**: 0 US dollars - **BENEPALI - Rest of World**: 453,200,000 US dollars - **BYOOVIZ - UNITED STATES**: 13,000,000 US dollars - **BYOOVIZ - Rest of World**: 19,400,000 US dollars - **Subtotal: Biosimilars - UNITED STATES**: 13,700,000 US dollars - **Subtotal: Biosimilars - Rest of World**: 715,400,000 US dollars - **FAMPYRA - UNITED STATES**: 0 US dollars - **FAMPYRA - Rest of World**: 1,400,000 US dollars - **FLIXABI - UNITED STATES**: 0 US dollars - **FLIXABI - Rest of World**: 52,600,000 US dollars - **FUMADERM And ADUHELM - UNITED STATES**: 400,000 US dollars - **FUMADERM And ADUHELM - Rest of World**: 1,700,000 US dollars - **Total Fumarate - UNITED STATES**: 819,700,000 US dollars - **Total Fumarate - Rest of World**: 606,800,000 US dollars - **IMRALDI - UNITED STATES**: 0 US dollars - **IMRALDI - Rest of World**: 190,200,000 US dollars - **Total Interferon - UNITED STATES**: 587,800,000 US dollars - **Total Interferon - Rest of World**: 357,800,000 US dollars - **Subtotal: Multiple Sclerosis - UNITED STATES**: 2,372,500,000 US dollars - **Subtotal: Multiple Sclerosis - Rest of World**: 1,666,400,000 US dollars - **Other - UNITED STATES**: 195,500,000 US dollars - **Other - Rest of World**: 1,700,000 US dollars - **PLEGRIDY - UNITED STATES**: 104,900,000 US dollars - **PLEGRIDY - Rest of World**: 145,200,000 US dollars - **QALSODY - UNITED STATES**: 30,100,000 US dollars - **QALSODY - Rest of World**: 56,800,000 US dollars - **Subtotal: Rare Disease - UNITED STATES**: 966,200,000 US dollars - **Subtotal: Rare Disease - Rest of World**: 1,188,000,000 US dollars - **Completed technology for SKYCLARYS (U.S.) - UNITED STATES**: 310,600,000 US dollars - **Completed technology for SKYCLARYS (U.S.) - Rest of World**: 209,900,000 US dollars - **SPINRAZA - UNITED STATES**: 625,500,000 US dollars - **SPINRAZA - Rest of World**: 921,300,000 US dollars - **TECFIDERA - UNITED STATES**: 168,500,000 US dollars - **TECFIDERA - Rest of World**: 511,200,000 US dollars - **TOFIDENCE - UNITED STATES**: 700,000 US dollars - **TOFIDENCE - Rest of World**: 0 US dollars - **TYSABRI product - UNITED STATES**: 965,000,000 US dollars - **TYSABRI product - Rest of World**: 700,400,000 US dollars - **VUMERITY - UNITED STATES**: 651,200,000 US dollars - **VUMERITY - Rest of World**: 95,600,000 US dollars - **ZURZUVAE - UNITED STATES**: 195,100,000 US dollars - **ZURZUVAE - Rest of World**: 0 US dollars - **Product revenue, net - UNITED STATES**: 3,547,900,000 US dollars - **Product revenue, net - Rest of World**: 3,571,500,000 US dollars - **Research and development**: 1,778,600,000 US dollars - **Selling, general and administrative**: 2,433,600,000 US dollars - **Amortization and impairment of acquired intangible assets**: 515,000,000 US dollars - **Gain on sale of priority review voucher, net**: 0 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 290,200,000 US dollars - **Other (income) expense, net**: 305,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 33,600,000 US dollars - **Restructuring charges**: 48,600,000 US dollars - **Acquired in-process research and development, upfront and milestone expense**: 471,800,000 US dollars - **Impairment of ROU asset**: 52,900,000 US dollars - **Revenue before reconciliation (calculated)**: 23,730,300,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 13,839,700,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. ## Chart details: Revenue by Product and Service (4 categories) - Page: https://plicit.ai/financials/biib/fy2025-annual-income-statement/revenue-by-product-and-service-4-categories - Chart image: https://plicit.ai/charts/biib-fy2025-annual-revenue-by-product-and-service-4-categories-sankey.png Income statement for 2025-01-01 through 2025-12-31. View: Product and service (4 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,890,600,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,404,200,000 US dollars - **Gross profit (calculated)**: 7,486,400,000 US dollars - **Operating expenses (calculated)**: 5,929,900,000 US dollars - **Operating profit (calculated)**: 1,556,500,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense**: 1,556,500,000 US dollars - **Income tax (benefit) expense**: 263,600,000 US dollars - **Net income**: 1,292,900,000 US dollars - **Product revenue, net**: 7,119,400,000 US dollars - **Revenue from anti-CD20 therapeutic programs**: 1,860,600,000 US dollars - **Alzheimer's collaboration revenue**: 177,700,000 US dollars - **Contract manufacturing, royalty and other revenue**: 732,900,000 US dollars - **Research and development**: 1,778,600,000 US dollars - **Selling, general and administrative**: 2,433,600,000 US dollars - **Amortization and impairment of acquired intangible assets**: 515,000,000 US dollars - **Gain on sale of priority review voucher, net**: 0 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 290,200,000 US dollars - **Other (income) expense, net**: 305,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 33,600,000 US dollars - **Restructuring charges**: 48,600,000 US dollars - **Acquired in-process research and development, upfront and milestone expense**: 471,800,000 US dollars - **Impairment of ROU asset**: 52,900,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Product and Service (15 categories) - Page: https://plicit.ai/financials/biib/fy2025-annual-income-statement/revenue-by-product-and-service-15-categories - Chart image: https://plicit.ai/charts/biib-fy2025-annual-revenue-by-product-and-service-15-categories-sankey.png Income statement for 2025-01-01 through 2025-12-31. View: Product and service (15 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,890,600,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,404,200,000 US dollars - **Gross profit (calculated)**: 7,486,400,000 US dollars - **Operating expenses (calculated)**: 5,929,900,000 US dollars - **Operating profit (calculated)**: 1,556,500,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense**: 1,556,500,000 US dollars - **Income tax (benefit) expense**: 263,600,000 US dollars - **Net income**: 1,292,900,000 US dollars - **Contract manufacturing revenue**: 679,400,000 US dollars - **Royalty and other revenue**: 53,500,000 US dollars - **Contract manufacturing, royalty and other revenue**: 732,900,000 US dollars - **AVONEX**: 695,500,000 US dollars - **BYOOVIZ**: 32,400,000 US dollars - **FLIXABI**: 52,600,000 US dollars - **IMRALDI**: 190,200,000 US dollars - **PLEGRIDY**: 250,100,000 US dollars - **Revenue from anti-CD20 therapeutic programs**: 1,860,600,000 US dollars - **Royalty revenue on sales of OCREVUS**: 1,414,900,000 US dollars - **Completed technology for SKYCLARYS (U.S.)**: 520,500,000 US dollars - **SPINRAZA**: 1,546,800,000 US dollars - **TOFIDENCE**: 700,000 US dollars - **TYSABRI product**: 1,665,400,000 US dollars - **ZURZUVAE**: 195,100,000 US dollars - **Research and development**: 1,778,600,000 US dollars - **Selling, general and administrative**: 2,433,600,000 US dollars - **Amortization and impairment of acquired intangible assets**: 515,000,000 US dollars - **Gain on sale of priority review voucher, net**: 0 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 290,200,000 US dollars - **Other (income) expense, net**: 305,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 33,600,000 US dollars - **Restructuring charges**: 48,600,000 US dollars - **Acquired in-process research and development, upfront and milestone expense**: 471,800,000 US dollars - **Impairment of ROU asset**: 52,900,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Business Segment by Product and Service - Page: https://plicit.ai/financials/biib/fy2025-annual-income-statement/revenue-by-business-segment-by-product-and-service - Chart image: https://plicit.ai/charts/biib-fy2025-annual-revenue-by-business-segment-by-product-and-service-sankey.png Income statement for 2025-01-01 through 2025-12-31. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,890,600,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,404,200,000 US dollars - **Gross profit (calculated)**: 7,486,400,000 US dollars - **Operating expenses (calculated)**: 5,929,900,000 US dollars - **Operating profit (calculated)**: 1,556,500,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense**: 1,556,500,000 US dollars - **Income tax (benefit) expense**: 263,600,000 US dollars - **Net income**: 1,292,900,000 US dollars - **Reportable Segment - Contract manufacturing, royalty and other revenue**: 732,900,000 US dollars - **Reportable Segment - Revenue from anti-CD20 therapeutic programs**: 1,860,600,000 US dollars - **Undisclosed (calculated)**: 7,297,100,000 US dollars - **Research and development**: 1,778,600,000 US dollars - **Selling, general and administrative**: 2,433,600,000 US dollars - **Amortization and impairment of acquired intangible assets**: 515,000,000 US dollars - **Gain on sale of priority review voucher, net**: 0 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 290,200,000 US dollars - **Other (income) expense, net**: 305,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 33,600,000 US dollars - **Restructuring charges**: 48,600,000 US dollars - **Acquired in-process research and development, upfront and milestone expense**: 471,800,000 US dollars - **Impairment of ROU asset**: 52,900,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Product and Service (5 categories) - Page: https://plicit.ai/financials/biib/fy2025-annual-income-statement/revenue-by-product-and-service-5-categories - Chart image: https://plicit.ai/charts/biib-fy2025-annual-revenue-by-product-and-service-5-categories-sankey.png Income statement for 2025-01-01 through 2025-12-31. View: Product and service (5 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,890,600,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,404,200,000 US dollars - **Gross profit (calculated)**: 7,486,400,000 US dollars - **Operating expenses (calculated)**: 5,929,900,000 US dollars - **Operating profit (calculated)**: 1,556,500,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense**: 1,556,500,000 US dollars - **Income tax (benefit) expense**: 263,600,000 US dollars - **Net income**: 1,292,900,000 US dollars - **Product revenue, net**: 7,119,400,000 US dollars - **Royalty and other revenue**: 53,500,000 US dollars - **Alzheimer's collaboration revenue**: 177,700,000 US dollars - **Contract manufacturing revenue**: 679,400,000 US dollars - **Revenue from anti-CD20 therapeutic programs**: 1,860,600,000 US dollars - **Research and development**: 1,778,600,000 US dollars - **Selling, general and administrative**: 2,433,600,000 US dollars - **Amortization and impairment of acquired intangible assets**: 515,000,000 US dollars - **Gain on sale of priority review voucher, net**: 0 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 290,200,000 US dollars - **Other (income) expense, net**: 305,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 33,600,000 US dollars - **Restructuring charges**: 48,600,000 US dollars - **Acquired in-process research and development, upfront and milestone expense**: 471,800,000 US dollars - **Impairment of ROU asset**: 52,900,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Product and Service (19 categories) - Page: https://plicit.ai/financials/biib/fy2025-annual-income-statement/revenue-by-product-and-service-19-categories - Chart image: https://plicit.ai/charts/biib-fy2025-annual-revenue-by-product-and-service-19-categories-sankey.png Income statement for 2025-01-01 through 2025-12-31. View: Product and service (19 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,890,600,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,404,200,000 US dollars - **Gross profit (calculated)**: 7,486,400,000 US dollars - **Operating expenses (calculated)**: 5,929,900,000 US dollars - **Operating profit (calculated)**: 1,556,500,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense**: 1,556,500,000 US dollars - **Income tax (benefit) expense**: 263,600,000 US dollars - **Net income**: 1,292,900,000 US dollars - **BENEPALI**: 453,200,000 US dollars - **IMRALDI**: 190,200,000 US dollars - **FLIXABI**: 52,600,000 US dollars - **BYOOVIZ**: 32,400,000 US dollars - **TOFIDENCE**: 700,000 US dollars - **TECFIDERA**: 679,700,000 US dollars - **VUMERITY**: 746,800,000 US dollars - **AVONEX**: 695,500,000 US dollars - **PLEGRIDY**: 250,100,000 US dollars - **TYSABRI product**: 1,665,400,000 US dollars - **FAMPYRA**: 1,400,000 US dollars - **ZURZUVAE**: 195,100,000 US dollars - **FUMADERM And ADUHELM**: 2,100,000 US dollars - **SPINRAZA**: 1,546,800,000 US dollars - **SKYCLARYS**: 520,500,000 US dollars - **QALSODY**: 86,900,000 US dollars - **Alzheimer's collaboration revenue**: 177,700,000 US dollars - **Contract manufacturing, royalty and other revenue**: 732,900,000 US dollars - **Revenue from anti-CD20 therapeutic programs**: 1,860,600,000 US dollars - **Research and development**: 1,778,600,000 US dollars - **Selling, general and administrative**: 2,433,600,000 US dollars - **Amortization and impairment of acquired intangible assets**: 515,000,000 US dollars - **Gain on sale of priority review voucher, net**: 0 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 290,200,000 US dollars - **Other (income) expense, net**: 305,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 33,600,000 US dollars - **Restructuring charges**: 48,600,000 US dollars - **Acquired in-process research and development, upfront and milestone expense**: 471,800,000 US dollars - **Impairment of ROU asset**: 52,900,000 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.